Spotlight on DTPa-HBV-IPVHib vaccine (Infanrix hexa™)

BioDrugs

Volumn 24, Issue 5, 2010, Pages 299-302

  Dhillon, Sohita ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Spotlights; Hib DTaP hepatitis B poliovirus vaccine, general

Indexed keywords

BACTERIAL POLYSACCHARIDE; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VIRUS ANTIBODY; POLYSACCHARIDE POLYRIBOSYLRIBITOL PHOSPHATE; PRIORIX TETRA; S (1,2 DICHLOROVINYL)CYSTEINE; SYNFLORIX; TETANUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; DIPHTHERIA; DROWSINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MENINGOCOCCOSIS; PATHOLOGICAL CRYING; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SKIN REDNESS; TETANUS;

DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFECTION CONTROL; MASS VACCINATION; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; TETANUS; VACCINES, COMBINED; VACCINES, CONJUGATE; WHOOPING COUGH;

EID: 77956160232     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11206690-000000000-00000     Document Type: Review

References (36)

1. Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa): a review of its use as primary and booster vaccination. Drugs 2010; 70 (8): 1021-1058
2. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000 Sep; 137 (3): 304-312
3. Arstegui J, Dal-Re R, D?ez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 2003 Sep 8; 21 (25-26): 3593-3600
4. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogeni-city of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004 Jun 2; 22 (17-18): 2226-2233
5. Avdicova M, Prikazsky V, Hudeckova H, et al. Immunogenicity and re-actogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002 Nov; 161 (11): 581-587
6. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004; 36 (8): 585-592
7. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluationofbooster vaccination. Hum Vaccin 2006 Nov 31;2(6): 249-254
8. Heininger U, Sanger R, Jacquet JM, et al. Booster immunization with a hex-avalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated po-liovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007 Jan 22; 25 (6): 1055-1063
9. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006; 81 (47): 445-452
10. Zinke M, Disselhoff J, Gartner B, et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin. Epub 2010 Feb 18
11. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009 Sep; 5 (9): 592-598
12. Steiner M,RamakrishnanG, Gartner B, et al. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10: 9
13. Giambi C, Bella A, Barale A, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008 Jul 28; 8: 100
14. Nolan T, Altmann A, Skeljo M, et al. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004 Nov 15; 23 (1): 14-20
15. Lim FS, Han HH, Jacquet JM, et al. Primary vaccination of infants against hepatitis Bcan becompleted usingacombined hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influ-enzae type B vaccine. Ann Acad Med Singapore 2007 Oct; 36 (10): 801-806
16. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002 Sep; 21 (9): 854-859
17. Omenaca F, Garcia-Sicilia J, Garca-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005 Dec; 116 (6): 1292-1298
18. Omenaca F, Garcia-Sicilia J, Boceta R, et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007 Sep; 26 (9): 824-829
19. Omenaca F, Garcia-Sicilia J, Garca-Corbeira P, et al. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 2007 Jan; 119 (1): e179-85
20. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2005 Jan; 24 (1): 70-77
21. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006 May 29; 24 (22): 4727-4736
22. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009 Apr; 28 Suppl. 4: S97-108
23. Tejedor JC, Omenaca F, Garca-Sicilia J, et al. Immunogenicity and reacto-genicity of a three-dose primary vaccination course with a combined diph-theria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004 Dec; 23 (12): 1109-1115
24. TejedorJC, OmenacaF,Garča-SiciliaJ,etal. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age. Pediatr Infect Dis J 2006 Oct 25; 10, 943-945
25. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and re-actogenicity of primary immunization with a hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006 Aug; 25 (8): 713-720
26. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered withabooster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007 Aug; 166 (8): 857-864
27. Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008 May 12; 26 (20): 2545-2552
28. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacyof acellular pertussis vaccine in early childhood after household exposure. JAMA 1996 Jan 3; 275 (1): 37-41
29. Greco D, Salmaso S, Mastrantonio P, et al. on behalf of the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996 Feb 8; 334 (6): 341-348
30. Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006 Sep; 118 (3): 978-984
31. European Medicines Agency. Infanrix hexa: summary of product character-istics [online]. Available from URL: http://www.ema.europa.eu/ humandocs/PDFs/EPAR/Infanrixhexa/H-296-PI-en.pdf [Accessed 2010 Apr 18]
32. Saenger R, Maechler G, Potreck M, et al. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib +HBV administered separately. Vaccine 2005 Jan 19; 23 (9): 1135-1143
33. Zepp F, Schmitt HJ, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009 Jun; 8 (6): 663-678
34. von Kries R, Toschke AM, Strassburger K, et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur J Pediatr 2005 Feb; 164 (2): 61-69
35. von Kries R. Comment on B. Zinka et al. Unexplained cases of sudden in-fant death shortly after hexavalent vaccination [letter]. Vaccine 2006 Jul 26; 24 (31-32): 5783-4; author reply 5785-5786
36. Vazquez L, Garcia F, Ruttimann R, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr 2008 Sep; 97 (9): 1243-9